CMIC Group pioneered the CRO business in Japan over 28 years ago. Since then CMIC has continued as a leading innovator in the industry and has expanded services to encompass the entire pharmaceutical value-chain. We pride ourselves on meeting customers where they are and with exactly what they need to move their products forward.
View our services below by selecting the phase of drug development that you are working in:
CMIC offers tailored solutions for pharmaceutical companies, medical device manufacturers, academia, bio-ventures and medical institutions. Using our collective strengths, we offer a broad range of services from preclinical research to practical applications.
Japanese Market Entry
Providing full pharmaceutical capabilities for overseas business partners to enter into Japan market.
Supporting our client’s clinical trials throughout the Asia Pacific region. Providing solutions for a range of therapeutic areas, registry study, observational study, phases II/III clinical trials, phase IV clinical trials, post-marketing surveillance.
Specialized oncology staff assists with strategic development planning, including regulatory interaction, conducting clinical studies and post-marketing promotion for companies that wish to enter into the field of oncology.
Established systems ready to implement and form development strategies and support every stage of the regenerative medicine lifecycle, including regulatory consulting, various nonclinical and clinical studies, and post-marketing.
OrphanPacific is a pharmaceutical company within CMIC Group, which provides wealth of experience in the field of orphan drugs: regulatory affairs, supply chain management, quality management and marketing strategy planning.
